"回到真相":从负面的IPF试验中学到的经验教训
Athina Trachalaki1,2, Anna L Lindahl3,2, Simone Petrarulo4,2
1Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.
Breathe (Sheffield, England)
|April 21, 2025
概括
异形性肺纤维化 (IPF) 药物开发面临挑战,因为新疗法的晚期试验如zinpentraxin alfa,ziritaxestat和pamrevlumab都失败了. 解决试验设计中的陷和采用创新的方法对于未来的IPF治疗成功至关重要.
科学领域:
- 肺部病理学 肺部病理学
- 临床药理学 临床药理学
- 生物统计学 生物统计学
背景情况:
- 异形性肺纤维化 (IPF) 是一种渐进的肺病,尽管存在像皮尔芬尼和宁泰达尼布这样的疗法,但有效治疗方法有限.
- 最近对新型IPF疗法的晚期临床试验产生了令人失望的结果,突出了药物开发中的挑战.
- "回归真相"的现象表明,积极的早期试验结果可能并不总是转化为后期疗效.
研究的目的:
- 检查三个关键的IPF新疗法 (zinpentraxin alfa,ziritaxestat,pamrevlumab) 的晚期临床试验,这些新疗法未能满足其主要终点.
- 根据这些试验失败,识别IPF药物开发中的常见陷和挑战.
- 提出创新的方法和方法来提高未来IPF临床试验的稳定性和成功率.
主要方法:
- 对新的IPF疗法进行三项特定晚期临床试验的审查和分析.
- 在试验设计中确定常见问题,包括样本大小,终点选择和背景治疗的整合.
- 探索用于未来药物开发的先进的统计和试验设计方法.
主要成果:
- 在晚期发育阶段,Zinpentraxin alfa,Ziritaxestat和pamrevlumab的试验失败了,这表明翻译有希望的早期结果存在重大障碍.
- 发现的关键挑战包括不充分的II期样本大小,过度依赖代用终点 (如强迫生命能力),以及难以管理并发性抗纤维菌治疗.
- 这些失败凸显了药物开发中的"回归到真相",早期的疗效信号可能无法在更大,后期的研究中得到证实.
结论:
- 在IPF药物开发中晚期失败需要对当前的临床试验策略进行重新评估.
- 实施适应性试验设计,贝叶斯统计和复合终点可以提高试验严格性.
- 平台试验为加速多种IPF疗法的测试提供了潜在的途径,最终旨在改善IPF患者的治疗结果和生存率.
更多相关视频
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
11.4K
04:44Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
19.6K
相关概念视频
01:23Negative Regulator Molecules
35.0K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.0K
01:17Hypothesis: Accept or Fail to Reject?
27.3K
The outcome of any hypothesis testing leads to rejecting or not rejecting the null hypothesis. This decision is taken based on the analysis of the data, an appropriate test statistic, an appropriate confidence level, the critical values, and P-values. However, when the evidence suggests that the null hypothesis cannot be rejected, is it right to say, 'Accept' the null hypothesis?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
27.3K